VCNX Stock Overview
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Vaccinex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.05 |
| 52 Week High | US$100.80 |
| 52 Week Low | US$4.43 |
| Beta | 0.70 |
| 1 Month Change | -11.16% |
| 3 Month Change | -26.76% |
| 1 Year Change | -91.75% |
| 3 Year Change | -98.71% |
| 5 Year Change | -99.64% |
| Change since IPO | -99.75% |
Recent News & Updates
Shareholder Returns
| VCNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.8% | 4.7% | 0.7% |
| 1Y | -91.7% | 2.7% | 23.9% |
Return vs Industry: VCNX underperformed the US Biotechs industry which returned 2.7% over the past year.
Return vs Market: VCNX underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| VCNX volatility | |
|---|---|
| VCNX Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VCNX's share price has been volatile over the past 3 months.
Volatility Over Time: VCNX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 39 | Maurice Zauderer | www.vaccinex.com |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer’s disease and has completed phase 2 study for treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer.
Vaccinex, Inc. Fundamentals Summary
| VCNX fundamental statistics | |
|---|---|
| Market cap | US$9.59m |
| Earnings (TTM) | -US$20.25m |
| Revenue (TTM) | US$570.00k |
16.8x
P/S Ratio-0.5x
P/E RatioIs VCNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VCNX income statement (TTM) | |
|---|---|
| Revenue | US$570.00k |
| Cost of Revenue | US$16.57m |
| Gross Profit | -US$16.00m |
| Other Expenses | US$4.25m |
| Earnings | -US$20.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.78 |
| Gross Margin | -2,807.72% |
| Net Profit Margin | -3,552.81% |
| Debt/Equity Ratio | -4.4% |
How did VCNX perform over the long term?
See historical performance and comparison